We are live on ! Find out more
CGA

Compound Global Advisors Portfolio holdings

AUM $3.22M
1-Year Est. Return 30.08%
This Fund
S&P 500
This Quarter Est. Return
+12.52%
1 Year Est. Return
+30.08%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$540M
AUM Growth
+$83.9M
Cap. Flow
+$29.3M
Cap. Flow %
5.42%
Top 10 Hldgs %
42.7%
Holding
40
New
5
Increased
15
Reduced
15
Closed
1

Top Buys

Rank Stock Value
1
GFL icon
GFL Environmental
GFL
+$13.4M
2
RPRX icon
Royalty Pharma
RPRX
+$13.2M
3
FISV
Fiserv Inc
FISV
+$13.1M
4
TTE icon
TotalEnergies
TTE
+$12.8M
5
EQT icon
EQT Corp
EQT
+$9.39M

Top Sells

Rank Stock Value
1
WAL icon
Western Alliance Bancorporation
WAL
+$9.96M
2
BP icon
BP
BP
+$9.94M
3
PHM icon
Pultegroup
PHM
+$7.91M
4
UNH icon
UnitedHealth
UNH
+$7.85M
5
MA icon
Mastercard
MA
+$6.47M

Sector Composition

Rank Sector Weight
1 Technology 17.89%
2 Healthcare 15.11%
3 Consumer Discretionary 11.8%
4 Industrials 11.61%
5 Materials 11.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCEP icon
26
Coca-Cola Europacific Partners
CCEP
$45.8B
$11.1M 2.05%
165,628
-32,699
-16% -$2M
AMD icon
27
Advanced Micro Devices
AMD
$880B
$8.65M 1.6%
+58,666
New +$6.91M
ULTA icon
28
Ulta Beauty
ULTA
$20.5B
$8.61M 1.59%
17,576
-7,903
-31% -$3.33M
ASML icon
29
ASML
ASML
$693B
$8.1M 1.5%
10,707
– –
BSX icon
30
Boston Scientific
BSX
$64.8B
$7.15M 1.32%
123,615
+27,860
+29% +$1.49M
AZN icon
31
AstraZeneca
AZN
$261B
$7.07M 1.31%
52,458
-4,071
-7% -$529K
NVO
32
Novo Nordisk
NVO
$213B
$6.18M 1.14%
59,705
+17,017
+40% +$1.68M
LLY icon
33
Eli Lilly
LLY
$1.06T
$5.88M 1.09%
10,079
+1,841
+22% +$1.07M
TMO icon
34
Thermo Fisher Scientific
TMO
$213B
$5.87M 1.09%
11,053
-2,937
-21% -$1.42M
SPGI icon
35
S&P Global
SPGI
$124B
$5.84M 1.08%
13,255
– –
IQV icon
36
IQVIA
IQV
$34.6B
$5.78M 1.07%
25,001
-22,692
-48% -$4.66M
PLD icon
37
Prologis
PLD
$135B
$5.51M 1.02%
41,314
– –
WPM icon
38
Wheaton Precious Metals
WPM
$50B
$5.48M 1.01%
111,070
– –
AAPL icon
39
Apple
AAPL
$4.72T
$5.23M 0.97%
27,177
-25,000
-48% -$4.62M
RPRX icon
40
CALL
Royalty Pharma
RPRX
$26.2B
– –
-626,412
Closed -$17M
1
2

Similar funds

RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
KI
Khan Imran $2.93M AUM
1IC
1922 Investment Company Houston, Texas $2.92M AUM 1.93% 1-Year Est. Return
WH
Wolfswood Holdings New York $2.84M AUM 30.46% 1-Year Est. Return
SRB
Sid R. Bass $2.53M AUM
BPM
Blue Pool Management Causeway Bay, Hong Kong $2.46M AUM 25.18% 1-Year Est. Return

Compound Global Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, Compound Global Advisors held 40 positions worth $540M, up 18% from $456M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Compound Global Advisors deployed $29.3M of net new capital in Q4 2023, opening 5 new positions and adding to 15 existing holdings. Its largest new stake was GFL Environmental: 441,369 shares worth $15.2M.

By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 14% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Western Alliance Bancorporation, an estimated $9.96M trimmed.

  • Compound Global Advisors's largest Q4 2023 buy was GFL Environmental: 441,369 shares worth $15.2M.
  • Compound Global Advisors added most to EQT Corp in Q4 2023, an estimated $9.39M increase.
  • Compound Global Advisors's biggest Q4 2023 reduction was Western Alliance Bancorporation, cutting an estimated $9.96M.
  • Compound Global Advisors's ten largest holdings make up 43% of its $540M portfolio in Q4 2023.
  • Compound Global Advisors opened 5 new positions and closed 1 in Q4 2023.
  • Compound Global Advisors's portfolio value rose 18% quarter-over-quarter to $540M.

Based on Compound Global Advisors's 13F filing for Q4 2023, filed 24 Jan 2024.